XNAS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Agios Pharmaceuticals posted Q1 2026 revenue of $20.7 million, up 137.7% from $8.7 million in Q1 2025, driven by the U.S. launch of AQVESME in thalassemia.
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 4,859,002 | $209,520,165 | — | 8/13/2024 |
| Vanguard Group | 5,594,353 | $152,278,288 | — | 1/29/2026 |
| State Street | 3,108,145 | $84,603,707 | — | 2/13/2026 |
| DE Shaw | 1,861,286 | $50,664,205 | — | 2/17/2026 |
| Citadel Advisors | 1,608,868 | $43,793,387 | — | 2/17/2026 |
| Millennium Management | 418,267 | $11,385,228 | — | 2/17/2026 |
| JP Morgan Chase | 312,077 | $8,494,735 | — | 2/11/2026 |
| Two Sigma | 300,156 | $8,170,246 | — | 2/17/2026 |
| Point72 | 200,000 | $5,444,000 | — | 2/17/2026 |
| AQR Capital | 27,926 | $754,002 | — | 2/17/2026 |
| Fidelity (FMR) | 24,334 | $662,380 | — | 2/17/2026 |